tbuckley/cabot-search huggingface dataset:
Esophageal reconstitution by simultaneous antegrade/retrograde endoscopy: re-establishing patency of the completely obstructed esophagus
Authors: D. Schembre, J. Dever, M. Glenn, S. Bayles, J. Brandabur, R. Kozarek
Journal: Endoscopy (2011)

Complete obstruction of the proximal esophagus is an uncommon complication of radiotherapy. Standard endoscopic dilation is not possible because no lumen exists. We describe a retrospective case series in which rendezvous endoscopy, tissue puncture, dilation, and stenting were used to restore function to a group of patients with complete esophageal obstruction. The series consisted of patients referred for complete esophageal obstruction after radiation therapy over 5 years. Ultimately, five patients underwent successful initial recanalization via rendezvous endoscopy. All patients were able to resume eating and four have been able to maintain oral alimentation with periodic dilation. One patient developed self-limited pneumomediastinum after needle puncture and cervical osteomyelitis after stenting, and another developed an anterior neck abscess after stenting. Rendezvous endoscopy can successfully treat complete esophageal obstruction resulting from radiation therapy. Temporary stenting may allow patients to swallow immediately and leave the hospital sooner but does not appear to reduce the need for subsequent dilation and may result in serious complications.
Abstract LB-65: Advocating for Cancer Patients
Authors: Belita Cowan
Journal: Cancer Research (2011)

Abstract The Lymphoma Foundation of America (LFA) is a national, nonprofit charity dedicated to helping cancer patients and their families. The organization provides support and counseling services, research, grants, a patient hotline, referrals, second opinions, information about patients' rights, and financial assistance to low-income families. LFA in comprised of a scientific panel of experts with backgrounds in epidemiology, genetic, and biomedical research. Peer-reviewed research reports are published by the Foundation. LFA's report entitled, “Do Pesticides Cause Lymphoma”, is a meta-analysis of the scientific literature on the association between pesticide exposures and nonhodgkin lymphoma. “Lymphoma and Solvents” is another well-known LFA-published report on the relationship between benzene and lymphoma. Each year, LFA selects promising, young university-based researchers for their outstanding work in cancer epidemiology to receive the “Young Scientist Award”. As part of the Foundation's education and outreach, it produces webcasts and partners with Patient Power to broadcast radio talk shows. These resources help patients gain the information needed to make appropriate decisions about their treatment options. The Foundation also takes an active role in national health policy. LFA served as the lead amicus organization in the Agent Orange case argued before the U.S. Supreme Court. Lymphoma Foundation of America also filed a precedent-setting Freedom of Information Act request with the National Cancer Institute (NCI). This FOIA request established the right of cancer patients to receive copies of their experimental treatment protocols in all federally-funded cancer clinical trials. LFA has testified at multiple congressional hearings on the environmental causes of cancer. Lymphoma Foundation of America is an independent nonprofit organization and does not accept drug company or medical industry funding. LFA is entirely supported by individuals and charitable foundations. The Lymphoma Foundation of America was founded in 1986 by lymphoma patients who came together to help each other recover from cancer. Today, LFA serves as a leading voice for the lymphoma patient community. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-65. doi:10.1158/1538-7445.AM2011-LB-65
Hyper-IgE Syndrome with Recurrent Infections — An Autosomal Dominant Multisystem Disorder
Authors: Bodo Grimbacher, Steven M. Holland, John I. Gallin, Frank Greenberg, Suvimol C. Hill, Harry L. Malech, Judith A. Miller, Anne C. O'Connell, Jennifer M. Puck
Journal: New England Journal of Medicine (1999)

The hyper-IgE syndrome with recurrent infections is a rare immunodeficiency characterized by recurrent skin and pulmonary abscesses and extremely elevated levels of IgE in serum. Associated facial and skeletal features have been recognized, but their frequency is unknown, and the genetic basis of the hyper-IgE syndrome is poorly understood.
Closure of a persistent esophagopleural fistula using an over-the-scope clipping device
Authors: I. Khamaysi, A. Suissa, K. Yassin, I. Gralnek
Journal: Endoscopy (2013)

Esophagopleural fistula (EPF) is considered to be a rare condition, usually occurring after pneumonectomy. When it does occur, it is accompanied by significant morbidity and the associated mortality is high [1].
Transient Aphasia as Late-Onset Seizure After Embolization for Dural Arteriovenous Malformation
Authors: Chio Okuyama, Yo Ushijima, Kenzo Suzuki, Yoko Kin, Mitsukuni Tokuhiro, Yasuhiko Nakano, Tsunehiko Nishimura
Journal: Clinical Nuclear Medicine (2003)

Tc-99m HMPAO single photon emission computed tomography was performed in a patient who had experienced aphasia for 3 days. The patient had a medical history of subarachnoid hemorrhage and intracranial hemorrhage. Both of these hemorrhages were related to a dural arteriovenous malformation that was embolized after the onset of the cerebral vascular events. Focal hyperperfusion was seen in the left temporal lobe adjacent to a perfusion defect corresponding to the old cerebral hemorrhage. The finding was interpreted as the focus of the patient's epilepsy. His aphasia resolved after the administration of anticonvulsant medication for several days.
GW25-e5358 The Analysis of Plasma Renin Level in Patients with Pheochromocytoma
Authors: Zhou Keming, Suofeiya Albulikem, Zhou Ling, Zhang Delian, Nuerguli Mamati, Wang Menghui, Kong Jianqiong, Li Nanfang
Journal: Journal of the American College of Cardiology (2014)
Abstract 4695: Elevated levels of biomarkers of volatile organic carcinogens and toxicants in Chinese women who regularly cook at home
Authors: Steven G. Carmella, Stephen S. Hecht, Adeline Seow, Mingyao Wang, Renwei Wang, Lei Meng, Woon-Puay Koh, Menglan Chen, Shaomei Han, Mimi C. Yu, Jian-Min Yuan
Journal: Cancer Research (2010)

Abstract Chinese women in Asia have higher rates of lung cancer than in many other places in the world. In China, the age standardized incidence rate for female lung cancer is 19.9 per 100,000 and in Singapore it is 17.5, while rates are far lower (1.5-9.2) in countries such as Vietnam, Indonesia, India, and Russia. Cigarette smoking is not the major risk factor for lung cancer in these women, nor is secondhand tobacco smoke exposure. Some studies demonstrate the role of fumes from indoor heating under special circumstances. However, multiple epidemiologic studies document an association between lung cancer in Chinese women and Chinese-style cooking with oils heated at high temperatures. Carcinogens and toxicants have been identified in fumes generated during high temperature cooking with various oils but there have been no biomarker studies to assess carcinogen and toxicant uptake in Chinese women who regularly cook at home. We quantified urinary mercapturic acid biomarkers of exposure to the volatile compounds acrolein, crotonaldehyde, benzene, 1,3-butadiene, and ethylene oxide; and urinary metabolites of the non-volatile combustion products pyrene and phenanthrene in 54 non-smoking, non alcohol-drinking Chinese women who reported regularly doing home cooking and 50 non-smoking, non-alcohol drinking women randomly selected from the Singapore Chinese Health Study as controls. Compared with controls, women who engaged in regular home cooking had significantly higher levels of mercapturic acids of acrolein [geometric mean 1959 pmol/mg creatinine (95% CI 1554-2467) vs.1370 (95% CI 1077-1742), P = 0.038], crotonaldehyde [geometric mean 231.6 pmol/mg creatinine (95% CI 193-277) vs. 142.2 (95% CI 118-171) P = 0.0004], and benzene [geometric mean 0.58 pmol/mg creatinine (95% CI 0.44-0.78) vs. 0.18 (95% CI 0.14-0.24) P &amp;lt; 0.0001]. No significant differences were found in levels of mercapturic acids of 1,3-butadiene or metabolites of pyrene and phenanthrene between the two groups whereas levels of the ethylene oxide mercapturic acid were significantly higher in the controls than in the cooking group. The higher levels of the mercapturic acid of benzene, a multi-organ carcinogen, in the women who cooked, are particularly notable. The results of this study showing increased exposure to the volatile toxicants and carcinogens acrolein, crotonaldehyde, and benzene in Chinese women who regularly cook provide a plausible lead for further investigating the role of volatile compounds generated during cooking as causes of lung cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4695.
Labour unveils 10 year plan to end "perilous" state of NHS
Authors: G. Iacobucci
Journal: BMJ (2015)

<h3>Background</h3> Metastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with generally poor prognosis. Treatment with vascular endothelial growth factor inhibitors or chemotherapy generates only short-lived responses. Recent research has suggested a role for combination checkpoint inhibition as first line treatment for metastatic sRCC. This therapy consists of induction with cytotoxic T-lymphocyte-associated protein 4 inhibitor, ipilimumab, administered with programmed cell death protein 1 (PD-1) inhibitor, nivolumab. After completion of four cycles of combination therapy, single-agent maintenance nivolumab is recommended until progression. Patients who progress on maintenance nivolumab are switched to alternate therapy. Herein, we present a case of a patient with RCC who progressed on maintenance nivolumab who, on retreatment with ipilimumab, demonstrated a significant response In addition, we summarize important findings to support the role of salvage ipilimumab in patients with sRCC. <h3>Case presentation</h3> A 46-year-old man presented with flank pain and hematuria, the work up of which noted a left kidney mass for which he underwent nephrectomy and was diagnosed with localized sRCC with 60% sarcomatoid differentiation. Within 3 months of nephrectomy, he presented with recurrent flank pain and was diagnosed with recurrence of disease. He was treated with ipilimumab 1 mg/kg and nivolumab 3 mg/kg for four doses and demonstrated a partial response. He was then transitioned to single agent nivolumab maintenance. After 3 months on maintenance therapy, he was noted to have progression of disease. Given prior response to immune check point combination, it was decided to rechallenge the patient with 1 mg/kg ipilimumab. After two doses of ipilimumab and nivolumab combination therapy, the patient was noted to have a partial response. He maintained a response for an additional 9 months and treatment was eventually discontinued due to grade 3 toxicity and progression. <h3>Conclusions</h3> This case report demonstrates the utility of retreatment with ipilimumab as a salvage option for patients progressing on maintenance PD-1 inhibitors in metastatic RCC. Further studies are needed to identify predictors of response and toxicity to this approach, as well as the optimal scheduling of ipilimumab with maintenance nivolumab.
A Novel Treatment for the Midaortic Syndrome
Authors: Heung Bae Kim, Khashayar Vakili, Biren P. Modi, Michael A. Ferguson, Ann P. Guillot, Kristina M. Potanos, Sanjay P. Prabhu, Steven J. Fishman
Journal: New England Journal of Medicine (2012)

In a 3-year-old girl with the midaortic syndrome, a tissue expander was used to induce longitudinal growth of the distal aorta over a period of 9 months. It was then possible to resect the stenotic segment and perform an end-to-end anastomosis of the normal portions of aorta.
Postextrasystolic Potentiation on Quantitative Gated SPECT
Authors: TATSUYA KAWASAKI, TOMOHIKO SAKATANI, HIROKI MANI, MITSUYOSHI HADASE, TADAAKI KAMITANI, SHINGO KAWASAKI, HIROKI SUGIHARA
Journal: Clinical Nuclear Medicine (2002)

KAWASAKI, TATSUYA M.D.; SAKATANI, TOMOHIKO M.D.; MANI, HIROKI M.D.; HADASE, MITSUYOSHI M.D.; KAMITANI, TADAAKI M.D.; KAWASAKI, SHINGO M.D.; SUGIHARA, HIROKI M.D. Author Information
SP0125 Co-morbidity in rheumatic diseases
Authors: L. Klareskog
Journal: Annals of the Rheumatic Diseases (2013)

Co-morbidities, i.e. diseases that have an increased frequency in patients with rheumatic disease as compared to the population, provide important challenges in diagnostics, therapeutics and prevention for all rheumatologists. Their occurrence depends on three different pathogenetic principles, and knowledge about these principles is important for all handling of these co-morbidities: First, co-morbidities may occur as a result of shared risk factors for the musculoskeletal disease and its co-morbidity. A prototype case for this is the co-existence of type I diabetes and ACPA-positive RA, where genetic risk factors are shared, and where the "co-morbidity" in T1D most often begins before the onset of RA. In this and other cases of co-morbidity due to shared risk factors, we need knowledge about the risk for specific co-morbidities and appreciate the diagnosis and treatment of those in parallel to the treatment of the rheumatic condition. Second, co-morbidities may occur as a result of the rheumatic condition (and not of its treatment). Prototype cases for this are cardiovascular disease and some lymphoid cancers, in particular lymphomas, which occur in increased frequency in several of the inflammatory rheumatic conditions. As these diseases depend on distinct manifestations of the rheumatic disease, increased knowledge of the relation between the rheumatic disease and its co-morbidity may allow efficient treatment as well as prevention of the co-morbidity. Thirdly, the co-morbidity may depend on our treatment of the rheumatic condition. This is typically the case for some infections as well as some more rare manifestations of other autoimmune diseases such as neurological inflammatory diseases after treatment with different immunosuppressant including biologicals. Here, we need deep knowledge about the adverse event spectrum of drugs that we use. For all these co-morbidities, there is a need for increased knowledge about who are at risk and what is the most efficient treatment of the combined morbidity. This lecture will also discuss how modern genetics and biomarker analysis, together with classical analysis of clinical signs and symptoms provide us with new means to handle these complex medical challenges. <h3>Disclosure of Interest</h3> None Declared
Laboratory Accuracy in Neonatal Bilirubin
Authors: Stanley F. Lo
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Long-term dysphagia due to bronchogenic cyst of the esophagus
Authors: M. Ghobakhlou, S. Fatemi, A. Dezfouli, F. Tirgary, M. Zali
Journal: Endoscopy (2012)

A 23-year-old woman attended our hospital with the complaint of progressive dysphagia over the past year, especially to solid foods. Upper endoscopy showed a bulging lesion, which was probably due to external pressure on the distal part of the esophagus ([Fig. 1]). Endoscopic ultrasound (EUS) revealed a 3 × 3 cm cystic lesion in the same region, suggestive of a duplication or bronchogenic cyst ([Fig. 2]). Thoracic computed tomography showed a cystic lesion located in the same region ([Fig. 3]).
Proposal of a New 18F-FDG PET/CT Predictor of Response in Rectal Cancer Treated by Neoadjuvant Chemoradiation Therapy and Comparison With PERCIST Criteria
Authors: Anna Margherita Maffione, Alice Ferretti, Sotirios Chondrogiannis, Lucia Rampin, Maria Cristina Marzola, Gaia Grassetto, Carlo Capirci, Patrick M. Colletti, Domenico Rubello
Journal: Clinical Nuclear Medicine (2013)

Purpose The aim of this study was to correlate PERCIST criteria and a new criterion developed in our center that we named PREDIST (PET Residual Disease in Solid Tumor) with tumor regression grade (TRG) classification of pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients affected by rectal cancer. Methods Seventy-three consecutive patients affected by locally advanced rectal cancer (LARC) were retrospectively included. FDG-PET/CT scans were performed at staging time and after the end of CRT (mean time 6.5 weeks). The analysis was performed by PERCIST criteria 1.0 and PREDIST criteria based on a new definition of residual disease. We split the TRG system into responders (TRG1-2) and nonresponders (TRG3-5). Pearson chi-square analysis by cross-tabulations was performed. Results PREDIST classification was statistically predictive of TRG response (P = 0.004, sensitivity 81.8% and specificity 54.9%). On the contrary, PERCIST criteria was not statistically correlated to TRG (P = 0.128) caused by a very low specificity (9.8%). Conclusions FDG-PET/CT scan is an accurate tool to predict preoperatively the response to CRT in LARC patients. The novel proposed criterion (PREDIST) seems to be helpful to discriminate responder by nonresponder patients.
CHILDREN FIRST STUDY II: HOW AN EDUCATIONAL PROGRAM IN CARDIOVASCULAR PREVENTION AT PUBLIC SCHOOLS CAN IMPROVE PARENTS’ CARDIOVASCULAR RISK
Authors: Luciana Fornari, Cristiano Pinto, Silvia Oyama, Manoela Rodrigues, Taciana Davanco, Daniela Calderaro, Bruno Caramelli
Journal: Journal of the American College of Cardiology (2015)
Abstract 3121: Systematic analysis of the DNA synthesis fidelity of somatic mutations of polymerase beta found in prostate cancer
Authors: Desheng Chen, Kimberly LeCompte, Zachary Pursell, Nick Makridakis
Journal: Cancer Research (2012)

Abstract Human DNA polymerase beta (polβ) is a monomeric protein of 335 amino acids and functions in base excision repair and meiotic recombination. Human polα is over-expressed in many cancer cells like ovarian, prostate, breast, colon and chronic myelogenous leukemia. To obtain clues of possible functions in vivo, we have determined the fidelity of DNA synthesis of polα with forward mutation assay which scored the sequence errors caused in the lacZ-α gene in M13mp2 during DNA synthesis to fill a 407-nucleotide gap. Three of seven of the somatic polα mutants, p.E232K, p.E123K and pE216K, which we identified previously in prostate tumors, were tested. The results indicated that the somatic mutants of human DNA polymerase beta display altered fidelity. The fidelity for large deletions and complex changes of the pE232K and pE123K muatants are three and 31 times lower respectively, compared to wild type polα. The T&amp;gt;G transversion at position 103, which is the most common feature of polB base substitution error spectrum, is observed six times and two times lower for the pE123K and p.E216K mutants than wild polymerase beta. Our data show that somatic mutations in prostate cancer change both the synthesis fidelity and/or mutation type compared with wild type polymerase beta. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3121. doi:1538-7445.AM2012-3121
AB0075 Toll-like receptor 3 and interleukine 1b expression in circulating progenitor cells isolated from patients with rheumatoid arthritis.
Authors: A. Lo Gullo, G. Mandraffino, M. A. Sardo, F. Mamone, R. Mandraffino, C. Saitta, R. Lo Gullo, A. G. Versace, M. Cinquegrani, A. Saitta
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Circulating progenitor cells (CPCs), including CD34+ cells and endothelial progenitor cells (EPCs), play a role in delaying atherosclerosis and cardiovascular disease. Toll-like receptor 3 (TLR3), a member of the pathogen recognition receptors that mediates immune response and activates inflammatory genes, is involved in the development of atherosclerosis. TLR3 has been recently detected in EPCs and its “in vitro” activation appears to induce cytokine expression and apoptosis. We measured the expression of TLR3 and Interleukine1β- mRNA in CPCs isolated from patients with rheumatoid arthritis. <h3>Objectives</h3> The aim was to evaluate whether systemic inflammation is associated with CPC number and CPC expression of TLR3 and IL-1β. <h3>Methods</h3> CD34+ cells were isolated from peripheral blood from 21 patients with rheumatoid arthritis (RA patients) and from 21 matched controls. TLR3 and IL-1β -RNA expression were measured in enriched sample of CD34+ cells. Plasma C-reactive protein (CRP) and fibrinogen levels were also measured. <h3>Results</h3> With respect to controls, CD34+ cell number was lower in RA patients. CRP and fibrinogen levels were higher in RA patients than in controls. TLR3-mRNA anf IL-1βexpression were significantly higher in RA patients with respect to controls. CRP and fibrinogen levels were associated with IL-1β e TLR3 expression; moreover, the increased expression of TLR3 and IL-1β were associated with lowering CPC number. <h3>Conclusions</h3> RA is associated to an increased expression of TLR3 and of IL-1β in CPCs, which appear to affect the decrease of CPC number. It is likely that this novel association may at least in part contribute to explain the increase of cardiovascular morbidity and mortality in patients suffering from RA. Further studies could clarify whether the modulation of TLR3 expression in CPCs may modify the CV risk in patients affected by RA. <h3>References</h3> Herbrig K et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 2006;65(2):157-63. Yang M et al. The functional expression of TLR3 in EPCs impairs cell proliferation by induction of cell apoptosis and cell cycle progress inhibition. Int Immunopharmacol 2011, 11(12):2118-2124. Raicevic G et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol 2010, 71(3):235-244. Ito C et al. Cilostazol enhances IL-1beta-induced NO production and apoptosis in rat vascular smooth muscle via PKA-dependent pathway. Cell Signal 2002, 14(7):625-632. Zimmer S et al. Activation of endothelial toll-like receptor 3 impairs endothelial function. Circ Res 2011, 108(11):1358-1366. <h3>Disclosure of Interest</h3> None Declared